Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 4
2011 3
2012 2
2013 1
2014 3
2015 4
2016 8
2017 6
2018 6
2019 5
2020 4
2021 3
2022 3
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

45 results
Results by year
Filters applied: . Clear all
Page 1
Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Minozzi S, Bonovas S, Lytras T, Pecoraro V, González-Lorenzo M, Bastiampillai AJ, Gabrielli EM, Lonati AC, Moja L, Cinquini M, Marino V, Matucci A, Milano GM, Tocci G, Scarpa R, Goletti D, Cantini F. Minozzi S, et al. Expert Opin Drug Saf. 2016 Dec;15(sup1):11-34. doi: 10.1080/14740338.2016.1240783. Expert Opin Drug Saf. 2016. PMID: 27924643 Free article. Review.
Areas covered: We conducted a systematic review and meta-analysis of published randomized studies to determine the effect of anti-TNF drugs on the occurrence of infectious adverse events (serious infections; tuberculosis; opportunistic infections; any infe …
Areas covered: We conducted a systematic review and meta-analysis of published randomized studies to determine the effect of anti-TNF drugs …
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
Li X, Andersen KM, Chang HY, Curtis JR, Alexander GC. Li X, et al. Ann Rheum Dis. 2020 Feb;79(2):285-291. doi: 10.1136/annrheumdis-2019-216102. Epub 2019 Oct 31. Ann Rheum Dis. 2020. PMID: 31672774 Free PMC article.
OBJECTIVE: To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients. ...By contras …
OBJECTIVE: To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an in …
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.
Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Bonovas S, et al. Clin Gastroenterol Hepatol. 2016 Oct;14(10):1385-1397.e10. doi: 10.1016/j.cgh.2016.04.039. Epub 2016 May 14. Clin Gastroenterol Hepatol. 2016. PMID: 27189910 Review.
Two reviewers independently extracted study data and outcomes (serious infections, opportunistic infections, tuberculosis, any infection, and malignancies) and rated each trial's risk of bias. ...CONCLUSIONS: On the basis of a systematic …
Two reviewers independently extracted study data and outcomes (serious infections, opportunistic infections, tuberculos …
Herpes zoster: Risk and prevention during immunomodulating therapy.
Tran CT, Ducancelle A, Masson C, Lunel-Fabiani F. Tran CT, et al. Joint Bone Spine. 2017 Jan;84(1):21-27. doi: 10.1016/j.jbspin.2016.04.001. Epub 2016 May 28. Joint Bone Spine. 2017. PMID: 27245419 Free article. Review.
Immunomodulating drugs can increase the risk of infection. Well-established risk factors include advanced age and glucocorticoid therapy. The data are somewhat conflicting for medications such as methotrexate, tofacitinib, TNFalpha antagonists (infliximab, ad …
Immunomodulating drugs can increase the risk of infection. Well-established risk factors include advanced age and gluco …
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, Mylonakis E, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J. Baddley JW, et al. Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S10-S20. doi: 10.1016/j.cmi.2017.12.025. Epub 2018 Feb 6. Clin Microbiol Infect. 2018. PMID: 29459143 Free article. Review.
CONTENT: Preclinical and clinical evidence indicate that anti-TNF-alpha therapy (infliximab, adalimumab, golimumab, certolizumab pegol and etanercept) is associated with a two-to four-fold increase in the risk of active tuberculosis and other granulomatous condition …
CONTENT: Preclinical and clinical evidence indicate that anti-TNF-alpha therapy (infliximab, adalimumab, golimumab, certolizumab pego …
Adverse effects of biologics: a network meta-analysis and Cochrane overview.
Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R. Singh JA, et al. Cochrane Database Syst Rev. 2011 Feb 16;2011(2):CD008794. doi: 10.1002/14651858.CD008794.pub2. Cochrane Database Syst Rev. 2011. PMID: 21328309 Free PMC article. Review.
Certolizumab pegol was associated with significantly higher risk of serious infections compared to control treatment (OR 3.51, 95% CI 1.59 to 7.79; NNTH = 17, 95% CI 7 to 68). ...Although the overall numbers are relatively small, certolizumab pegol was associ …
Certolizumab pegol was associated with significantly higher risk of serious infections compared to control treatment (O …
Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases.
Holmer A, Singh S. Holmer A, et al. Expert Rev Clin Immunol. 2019 Sep;15(9):969-979. doi: 10.1080/1744666X.2019.1646127. Epub 2019 Jul 25. Expert Rev Clin Immunol. 2019. PMID: 31322018 Free PMC article. Review.
While several randomized trials and indirect comparisons have informed the comparative efficacy of medications, there has been a limited synthesis of safety of different agents. Areas covered: We focus on the overall and comparative risk of serious and opportunistic …
While several randomized trials and indirect comparisons have informed the comparative efficacy of medications, there has been a limited syn …
Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Wang S, He Q, Shuai Z. Wang S, et al. Clin Rheumatol. 2018 Feb;37(2):439-450. doi: 10.1007/s10067-017-3966-1. Epub 2017 Dec 30. Clin Rheumatol. 2018. PMID: 29290076
The risk of serious infections has no difference and numerically was only slightly increased in patients with AS and nr-axSpA treated by biologics compared with controls (OR = 1.42; 95%CI 0.58-3.47). ...The use of biologics among patients with AS and nr-axSpA …
The risk of serious infections has no difference and numerically was only slightly increased in patients with AS and nr …
Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
Zhou HY, Guo B, Lufumpa E, Li XM, Chen LH, Meng X, Li BZ. Zhou HY, et al. Immunol Invest. 2021 May;50(4):323-337. doi: 10.1080/08820139.2020.1714650. Epub 2020 Feb 2. Immunol Invest. 2021. PMID: 32009472
However, more safety and maintenance studies need to be conducted in future for the acquisition of more accurate results.Abbreviations: FMT: Fecal microbiota transplantation; UC: Ulcerative colitis; RCTs: Randomized controlled trials; IBD: Inflammatory bowel disease; CD: Crohn' …
However, more safety and maintenance studies need to be conducted in future for the acquisition of more accurate results.Abbreviations: FMT: …
Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis.
Li J, Zhang Z, Wu X, Zhou J, Meng D, Zhu P. Li J, et al. Front Pharmacol. 2021 Nov 1;12:746396. doi: 10.3389/fphar.2021.746396. eCollection 2021. Front Pharmacol. 2021. PMID: 34790122 Free PMC article. Review.
A total of 23 articles were used for meta-analysis. The Cochrane Collaboration's risk of bias tool was used to assess the methodological quality of the included studies. ...Results: Treatment with anti-TNFalpha agents resulted in an increase in the risk of …
A total of 23 articles were used for meta-analysis. The Cochrane Collaboration's risk of bias tool was used to assess the meth …
45 results